U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07162363) titled 'Synergistic Minimally Invasive Surgery Plus Alteplase and Deferoxamine in ICH' on Aug. 19.
Brief Summary: This is a single-center, randomized, open-label pilot trial designed to evaluate the safety, feasibility, and preliminary efficacy of combining minimally invasive surgery (MIS) plus intralesional alteplase and intravenous deferoxamine (DFX) for the treatment of spontaneous intracerebral hemorrhage (ICH), compared with MIS plus alteplase or standard medical care. A total of 63 patients (21 per arm) will be enrolled and followed for 90 days.
Patients in the investigational arm will undergo MIS with intralesional alteplase admini...